Title:An Investigation of the Anti-Parkinsonism Potential of Co-enzyme Q10 and Co-enzyme Q10 /Levodopa-carbidopa Combination in Mice
Volume: 14
Issue: 1
Author(s): Olakunle J. Onaolapo, Ademola O. Odeniyi, Stephen O. Jonathan, Moyinoluwa O. Samuel, Deborah Amadiegwu, Ajoke Olawale, Aisha O. Tiamiyu, Folusho O. Ojo, Hameed A. Yahaya, Oluwadamilare J. Ayeni and Adejoke Y. Onaolapo*
Affiliation:
- Department of Anatomy, Ladoke Akintola University of Technology, Ogbomosho, Oyo State,Nigeria
Keywords:
Antioxidant, dopamine, electron transfer chain, neurobehaviour, Parkinson's disease, intraperitoneal.
Abstract:
Background: Despite decades of research, neurodegenerative disorders like Parkinson’s
disease remain a leading cause of disability worldwide, due to the insufficient reduction of disease
burden by available medications. Recently, the benefits of dietary supplements like co-enzyme Q10
in neurodegenerative diseases have been reported.
Aim: The protective effects of supplemental co-enzyme Q
10 (CQ
10) and possible additive benefits
of CQ
10/Levodopa-Carbidopa (LD) in Chlorpromazine (CPZ)-induced Parkinsonism-like changes
in mice were investigated.
Methods: Male mice were assigned to ten groups of 30 mice each. Groups included: Vehicle control
(fed Standard Diet (SD), and given intraperitoneal {ip} plus oral saline), LD group (fed SD, and given
ip saline plus oral LD), two groups fed CQ
10-supplemented diet (at 60 and 120 mg/kg of feed), and
given ip plus oral saline, CPZ group (fed SD, and given ip CPZ plus oral saline), CPZ/LD group (fed
SD, and given ip CPZ plus oral LD), two groups fed CQ
10-supplemented diet (at 60 and 120 mg/kg of
feed) and given ip CPZ plus oral saline, and another two groups fed CQ
10-supplemented diet (at 60
and 120 mg/kg of feed) and given ip CPZ plus oral LD. The total duration of study was 21 days, and
treatments were administered daily. Bodyweight and food intake were measured weekly, while neurobehavioural
and biochemical tests were assessed at the end of the experimental period.
Results: CQ
10-supplementation was protective against CPZ-induced parkinsonism-like changes including,
reduction in mortality, the reversal of retardation of open-field behaviours and reduction of
catalepsy, increase in dopamine levels and decreased oxidative stress. CQ
10 also showed significant
improvements in these parameters when co-administered with LD. CQ
10 (in groups administered
CPZ/CQ
10 60) showed greater benefit over LD on anxiety-related behaviours and also had additive
benefits on working-memory.
Conclusion: Dietary CQ
10-supplementation was associated with demonstrable benefits in CPZinduced
Parkinsonism-like changes in mice.
